VERSAMEB
Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational since 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab ben... ch to patient. Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts. The pipeline includes lead candidate programs in stress urinary incontinence (SUI), solid tumors and rare diseases. Versameb is working towards the completion of a first in-human proof-of-concept clinical study while advancing its platform.
VERSAMEB
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2017-07-31
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.versameb.com
Total Employee:
11+
Status:
Active
Total Funding:
26.65 M CHF
Technology used in webpage:
Google Maps Amazon Google Maps API Pound Sterling Amazon Frankfurt Region FreshService Hostpoint
Similar Organizations
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Evaxion Biotech
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.
Rapt Therapeutics
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
Holiferm
Holiferm develops holistically improved fermentation technology for massive economic improvements.
New Amsterdam Pharma
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
PolyModels Hub
Accelerate drug development with modeling, simulations, and data
Spexis
Spexis is a swiss pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs.
UniQure
uniQure is focused on the research and early development of human gene-based therapies.
Current Advisors List
Board_member
2021-04-28
Board_member
2023-05-11
Board_member
2023-01-24
Board_member
2023-05-11
Board_member
2018-03-18
Board_member
2021-05-11
Current Employees Featured
Klaas Zuideveld Chief Executive Officer @ Versameb
Chief Executive Officer
2020-11-01
Roger R. Dmochowski Chief Medical Officer @ Versameb
Chief Medical Officer
2023-10-01
Elisabeth Svanberg Medical Monitor / Clinical Operations Consultant @ Versameb
Medical Monitor / Clinical Operations Consultant
2023-02-22
Justin Antony Selvaraj Senior Technology Director @ Versameb
Senior Technology Director
2019-04-01
Isabel Ferreira Chief Business Officer @ Versameb
Chief Business Officer
2019-08-01
Tatsuo Satoh Operations Director @ Versameb
Operations Director
2019-04-01
Beatrix Oppenberg CMC Director @ Versameb
CMC Director
2022-04-01
Sina Zimmerli Research associate @ Versameb
Research associate
2019-01-01
Pascale Cordasco Senior Associate @ Versameb
Senior Associate
2018-05-01
Isabelle Kappeler HR and Project Manager @ Versameb
HR and Project Manager
2018-03-18
Founder
Investors List
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Bernina BioInvest
Bernina BioInvest investment in Seed Round - Versameb
Key Employee Changes
| Date | New article |
|---|---|
| 2023-06-21 | Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer |
Official Site Inspections
http://www.versameb.com Semrush global rank: 3.96 M Semrush visits lastest month: 2.78 K
- Host name: sl2199.web.hostpoint.ch
- IP address: 217.26.55.168
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Versameb"
Versameb - Crunchbase Company Profile & Funding
Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to …See details»
Versameb AG - LinkedIn
Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to ...See details»
Versameb Company Profile | Management and Employees List
Versameb Profile and History. Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein …See details»
Versameb AG - Swiss Biotech
Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in …See details»
Versameb - app.biopharmiq.com
Description: Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the …See details»
Versameb - VentureRadar
" Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting, including the …See details»
Delving into the Latest Updates on Versameb AG with Synapse
Contact for media enquiries: Versameb Dr Klaas Zuideveld, CEO ir@versameb.com Stern Investor Relations, Inc. Janhavi Mohite +1 212-362-1200 janhavi.mohite@sternir.com …See details»
Versameb - Switzerland Innovation Park Basel Area
Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting. Versameb’s …See details»
Versameb - Leadership Team - The Org
The Leadership Team at Versameb drives the strategic vision and operational management of the company, overseeing the discovery and development of innovative RNA-based drugs. This …See details»
Versameb Company Profile - Office Locations, Competitors ... - Craft
Versameb has 5 employees at their 1 location and $18.21 m in total funding,. See insights on Versameb including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
company - versameb
Company. Versameb AG is a privately held company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting, …See details»
Versameb - Products, Competitors, Financials, Employees, …
Versameb's VERSagile technology platform supports the application of functional RNA in different disease contexts, with the goal of expanding the use of RNA therapeutics. It was founded in …See details»
Versameb Company Information - Funding, Investors, and More
Versameb is a Basel-based biotechnology company focusing on discovering and developing RNA-based drugs for modulation of protein expression. Seedtable Score 76 Startups 4See details»
Versameb - Contacts, Employees, Board Members, Advisors
Versameb has 13 current employee profiles, including Chief Executive Officer Klaas Zuideveld. Versameb has 6 board members and advisors, including Bettina Ernst . ContactsSee details»
Versameb | CipherBio
Explore Versameb's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Versameb AG Announces Grant of First Patent in China for "Signal ...
2 days ago Versameb AG is a privately held biotechnology company focused on discovering and developing innovative RNA-based therapeutics. Founded in Basel in 2018, Versameb is led by …See details»
Versameb AG - top100startup.ch
Oct 17, 2019 Milestones. 16.11.2023 Versameb Announces FDA Clearance of IND Application for VMB-100 in the Treatment of Stress Urinary Incontinence; 15.07.2020 Versameb raises …See details»
Versameb AG Announces Grant of First Patent in China for "Signal ...
1 day ago Versameb AG ("Versameb"), a clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the issuance of the Notice of …See details»
Pipeline - versameb
Versameb is building a pipeline of promising new first-in-class RNA therapeutics leveraging a next generation platform technology as we progress our current assets towards the clinic. …See details»
Versameb raises 6 million Swiss francs
Jul 17, 2020 The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is …See details»